Lamivudine

Jennifer Audsley, Michelle Giles, Sharon R. Lewin

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

Abstract

Lamivudine is the negative enantiomer of 2'-deoxy-3'- thiacytidine, the racemic mixture of the two enantiomers previously known as both BCH 189 and GR103365X. It is a member of the nucleoside analog reverse transcriptase inhibitor class of antiretroviral drugs. This dideoxynucleoside analog of cytidine is a potent inhibitor of HIV-1 and HIV-2, as well as of hepatitis B virus. Lamivudine- manufactured by GlaxoSmithKline, approved by the US Food and Drug Administration (FDA) approved in 1995, and marketed by ViiV Healthcare-is registered for the treatment of HIV-1 infection and hepatitis B virus infection in a number of countries. Its trade name is Epivir, but it also comes in a number of fixed formulations, including with zidovudine (Combivir), with zidovudine and abacavir (Trizivir), and with abacavir as a single tablet (Kivexa, Epzicom). A tenofovir-lamivudine combination tablet, manufactured by Hetero Drugs in India, was approved by the FDA for use outside the USA (US Food and Drug Administration, 2009).

Original languageEnglish
Title of host publicationKucers the Use of Antibiotics
Subtitle of host publicationA Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs
EditorsM. Lindsay Grayson
Place of PublicationBoca Raton FL USA
PublisherCRC Press
Pages3729-3754
Number of pages26
Edition7th
ISBN (Electronic)9781498747967
ISBN (Print)9781498747950
Publication statusPublished - 2 Oct 2017

Cite this

Audsley, J., Giles, M., & Lewin, S. R. (2017). Lamivudine. In M. L. Grayson (Ed.), Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs (7th ed., pp. 3729-3754). CRC Press.